Skip to main content
Erschienen in: Diabetologia 12/2014

01.12.2014 | Meta-Analysis

Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis

verfasst von: Sebhat Erqou, C. Christine Lee, Amanda I. Adler

Erschienen in: Diabetologia | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypotheses

Current evidence indicates that statins increase the risk of incident diabetes; however, the relationship between statins and glycaemic control in people with established diabetes has not been well characterised. To address this question, we conducted a meta-analysis of randomised controlled trials (RCTs) of statins in patients with diabetes for whom there was available data on glycaemic control.

Methods

We identified studies published between January 1970 and November 2013 by searching electronic databases and reference lists. We included RCTs in which the intervention group received statins and the control group received placebo or standard treatment, with >200 participants enrolled, with the intervention lasting >12 weeks and with pre- and post-intervention HbA1c reported. We combined study-specific estimates using random-effects model meta-analysis.

Results

In a pooled analysis of nine trials involving 9,696 participants (4,980 statin, 4,716 control) and an average follow-up of 3.6 years, the mean HbA1c of participants randomised to statins was higher than those randomised to the control group: mean difference (95% CI) was 0.12% (0.04, 0.20) or 1.3 mmol/mol (0.4, 2.2); p = 0.003. There was moderate heterogeneity across the studies (I 2 = 54%, p = 0.014) not explained by available study-level characteristics. This review was limited by the small number of studies, available data on only three statins and sparse reporting on changes in use of glucose-lowering medications.

Conclusions/interpretation

Statin treatment is associated with a modest increase in HbA1c in patients with diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef
2.
Zurück zum Zitat Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 37:117–125 Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 37:117–125
3.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421 Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421
4.
Zurück zum Zitat Rocco MB (2012) Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 79:883–893PubMedCrossRef Rocco MB (2012) Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 79:883–893PubMedCrossRef
5.
Zurück zum Zitat Stone NJ, Robinson J, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2):S1–S45PubMedCrossRef Stone NJ, Robinson J, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2):S1–S45PubMedCrossRef
6.
Zurück zum Zitat Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef
7.
Zurück zum Zitat Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N (2014) An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol 8(3 Suppl.):S17–S29PubMedCrossRef Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N (2014) An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol 8(3 Suppl.):S17–S29PubMedCrossRef
8.
Zurück zum Zitat Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564PubMedCrossRef Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564PubMedCrossRef
9.
Zurück zum Zitat Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346:f2610PubMedCentralPubMedCrossRef Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346:f2610PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Sasaki J, Iwashita M, Kono S (2006) Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 13:123–129PubMedCrossRef Sasaki J, Iwashita M, Kono S (2006) Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 13:123–129PubMedCrossRef
11.
Zurück zum Zitat Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A (2006) Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 13:95–100PubMedCrossRef Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A (2006) Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 13:95–100PubMedCrossRef
12.
Zurück zum Zitat Kei A, Liberopoulos E, Elisaf M (2013) Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 4:365–371PubMedCentralPubMedCrossRef Kei A, Liberopoulos E, Elisaf M (2013) Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 4:365–371PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Simsek S, Schalkwijk CG, Wolffenbuttel BH (2012) Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes—the CORALL study. Diabet Med 29:628–631PubMedCrossRef Simsek S, Schalkwijk CG, Wolffenbuttel BH (2012) Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes—the CORALL study. Diabet Med 29:628–631PubMedCrossRef
14.
Zurück zum Zitat Liu PY, Lin LY, Lin HJ et al (2013) Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLOS ONE 8:e76298 Liu PY, Lin LY, Lin HJ et al (2013) Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLOS ONE 8:e76298
15.
Zurück zum Zitat Chapman MJ, Orsoni A, Robillard P, Hounslow N, Sponseller CA, Giral P (2014) Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 30:775–784PubMedCrossRef Chapman MJ, Orsoni A, Robillard P, Hounslow N, Sponseller CA, Giral P (2014) Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 30:775–784PubMedCrossRef
16.
Zurück zum Zitat Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M (1994) A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes. Clin Cardiol 17:558–562PubMedCrossRef Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M (1994) A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes. Clin Cardiol 17:558–562PubMedCrossRef
17.
Zurück zum Zitat Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y (2008) Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 15:269–275PubMedCrossRef Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y (2008) Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 15:269–275PubMedCrossRef
18.
Zurück zum Zitat Gumprecht J, Gosho M, Budinski D, Hounslow N (2011) Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 13:1047–1055PubMedCrossRef Gumprecht J, Gosho M, Budinski D, Hounslow N (2011) Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 13:1047–1055PubMedCrossRef
19.
Zurück zum Zitat Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA (2009) Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52:50–59PubMedCrossRef Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA (2009) Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52:50–59PubMedCrossRef
20.
Zurück zum Zitat Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR (2010) Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 213:512–517PubMedCrossRef Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR (2010) Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 213:512–517PubMedCrossRef
21.
Zurück zum Zitat Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952PubMedCrossRef Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952PubMedCrossRef
22.
Zurück zum Zitat Konduracka E, Galicka-Latala D, Cieslik G et al (2008) Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab 10:719–725PubMedCrossRef Konduracka E, Galicka-Latala D, Cieslik G et al (2008) Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab 10:719–725PubMedCrossRef
23.
Zurück zum Zitat Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef
24.
Zurück zum Zitat Knopp RH, d′Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29:1478–1485PubMedCrossRef Knopp RH, d′Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29:1478–1485PubMedCrossRef
25.
Zurück zum Zitat Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef
26.
Zurück zum Zitat Tajima N, Kurata H, Nakaya N et al (2008) Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Atherosclerosis 199:455–462PubMedCrossRef Tajima N, Kurata H, Nakaya N et al (2008) Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Atherosclerosis 199:455–462PubMedCrossRef
27.
Zurück zum Zitat Diabetes Atorvastin Lipid Intervention Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335–1341CrossRef Diabetes Atorvastin Lipid Intervention Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335–1341CrossRef
28.
Zurück zum Zitat Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef
29.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef
30.
Zurück zum Zitat Nordin G, Dybkaer R (2007) Recommendation for term and measurement unit for ‘HbA1c’. Clin Chem Lab Med 45:1081–1082PubMedCrossRef Nordin G, Dybkaer R (2007) Recommendation for term and measurement unit for ‘HbA1c’. Clin Chem Lab Med 45:1081–1082PubMedCrossRef
31.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
34.
Zurück zum Zitat Cholesterol Treatment Trialists (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590CrossRef Cholesterol Treatment Trialists (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590CrossRef
35.
Zurück zum Zitat Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef
36.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef
37.
Zurück zum Zitat Goldfine AB (2012) Statins: is it really time to reassess benefits and risks? N Engl J Med 366:1752–1755PubMedCrossRef Goldfine AB (2012) Statins: is it really time to reassess benefits and risks? N Engl J Med 366:1752–1755PubMedCrossRef
38.
Zurück zum Zitat Yada T, Nakata M, Shiraishi T, Kakei M (1999) Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 126:1205–1213PubMedCentralPubMedCrossRef Yada T, Nakata M, Shiraishi T, Kakei M (1999) Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 126:1205–1213PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Mabuchi H, Higashikata T, Kawashiri M et al (2005) Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12:111–119PubMedCrossRef Mabuchi H, Higashikata T, Kawashiri M et al (2005) Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12:111–119PubMedCrossRef
40.
Zurück zum Zitat Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T (2006) Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49:1881–1892PubMedCrossRef Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T (2006) Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49:1881–1892PubMedCrossRef
41.
Zurück zum Zitat Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56:2328–2338PubMedCrossRef Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56:2328–2338PubMedCrossRef
Metadaten
Titel
Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
verfasst von
Sebhat Erqou
C. Christine Lee
Amanda I. Adler
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 12/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3374-x

Weitere Artikel der Ausgabe 12/2014

Diabetologia 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.